HOLLYWOOD, CA--(Marketwire - April 13, 2011) -
| Highlighted Links |
|
Erwin Bouwens, CEO of Genmed Holding Corp. (OTCBB: GENM), will be interviewed this afternoon at 3PM EDT by Wall Street Reporter, a leading online, market news provider that has been online since 1997, and traces its heritage to 1843 as the first financial newspaper published in the United States. Wall Street Reporter brings current news and market insight to investors and gives investors direct access to CEOs of promising, publicly traded companies.
Wall Street Reporter’s global investor audience consists primarily of hedge fund managers, investment advisors, analysts, investment bankers, and self-directed individual investors managing over $2 trillion in capital worldwide.
Wall Street Reporter’s purpose is to help investors worldwide discover profitable trading and investing ideas. Today, Wall Street Reporter is best known as a “bridge” connecting serious investors directly with management of high-potential public companies.
Known for their exclusive CEO Interviews, the publication enables company management to share their company’s “investment story” in their own words, in a candid way, without media bias, or filtering. This management access gives investors a profitable edge, enabling them to understand a company’s upside potential, in the proper context, straight from the source.
Bouwens stated late yesterday that he is overwhelmed by the response that Scripted Consulting has garnered and understands that there are many more interviews to follow over the next several weeks.
If you are interested in learning more about this innovative company, please reference their stock symbol GENM or visit the Genmed website at www.genmed.nl.
About Genmed Holding Corp.
Genmed Holding Corp. is a fully reporting publicly traded company that trades on the OTC under the symbol GENM. It is a United States and Dutch based company focusing on the delivery of low cost generic pharmaceutical drugs directly to distribution channels throughout the world. The Company began its generic drug business in 2008 and today operates primarily through its 100% owned subsidiary Genmed B.V., which is registered in the Netherlands. The Company is led by an experienced management team and board who have considerable and highly relevant experience in product development, registration, sales, marketing, distribution, operations, and financial administration.
For Additional Information, Go to the Website: www.genmed.nl
This press release contains certain “forward-looking statements” within the meaning of federal securities laws including the use of the words “expect,” “anticipate,” “estimate,” “project,” “forecast,” “outlook,” “target,” “objective,” “plan,” “goal,” “pursue,” “on track,” and similar expressions. Although the Company believes that the statements were reasonable when made, these forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of our products and services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management or increased government regulations.
Digg this 
Bookmark with del.icio.us 
Add to Newsvine
Technorati: generic drugs pharmaceutical genmed Erwin Bouwens Wall Street Reporter
